IMDX - Oncocyte Corp

3.56
-0.550   -15.449%

Share volume: 340,999
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.08%

PREVIOUS CLOSE
CHG
CHG%
$4.11
-0.55
-0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 8%
Dept financing 8%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.00%
1 Month
-27.94%
3 Months
-46.30%
6 Months
10.22%
1 Year
10.90%
2 Year
21.50%
Key data
Stock price
$3.56
P/E Ratio 
N/A
DAY RANGE
$3.29 - $4.37
EPS 
-$1.65
52 WEEK RANGE
$2.33 - $8.51
52 WEEK CHANGE
$16.34
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
32.168 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.37
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$216,059
AVERAGE 30 VOLUME 
$142,837
Company detail
CEO: Joshua Riggs
Region: US
Website: oncocyte.com
Employees: 120
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services.

Recent news